Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
= 33 34 33 34 O
1,000 35 40 35 40 B-lower_bound
/ 40 41 40 41 I-lower_bound
uL 41 43 41 43 I-lower_bound

Additional 0 10 44 54 O
exclusion 11 20 55 64 O
criteria 21 29 65 73 O
for 30 33 74 77 O
exploratory 34 45 78 89 O
cohort 46 52 90 96 O
ONLY 53 57 97 101 O
: 57 58 101 102 O
Known 59 64 103 108 O
pulmonary 65 74 109 118 B-chronic_disease
hypertension 75 87 119 131 I-chronic_disease

Any 0 3 132 135 O
condition 4 13 136 145 O
which 14 19 146 151 O
in 20 22 152 154 O
the 23 26 155 158 O
Investigator 27 39 159 171 O
's 39 41 171 173 O
opinion 42 49 174 181 O
deems 50 55 182 187 O
the 56 59 188 191 O
patient 60 67 192 199 O
an 68 70 200 202 O
unsuitable 71 81 203 213 O
candidate 82 91 214 223 O
to 92 94 224 226 O
receive 95 102 227 234 O
study 103 108 235 240 B-treatment
drug 109 113 241 245 I-treatment
( 114 115 246 247 O
i.e. 115 119 247 251 O
, 119 120 251 252 O
any 121 124 253 256 O
significant 125 136 257 268 O
medical 137 144 269 276 O
illness 145 152 277 284 O
or 153 155 285 287 O
abnormal 156 164 288 296 O
laboratory 165 175 297 307 O
finding 176 183 308 315 O
that 184 188 316 320 O
would 189 194 321 326 O
, 194 195 326 327 O
in 196 198 328 330 O
the 199 202 331 334 O
investigator 203 215 335 347 O
's 215 217 347 349 O
judgment 218 226 350 358 O
, 226 227 358 359 O
increase 228 236 360 368 O
the 237 240 369 372 O
patient 241 248 373 380 O
's 248 250 380 382 O
risk 251 255 383 387 O
by 256 258 388 390 O
participating 259 272 391 404 O
in 273 275 405 407 O
this 276 280 408 412 O
study 281 286 413 418 O
) 286 287 418 419 O

Any 0 3 420 423 O
human 4 9 424 429 B-clinical_variable
leukocyte 10 19 430 439 I-clinical_variable
antigen 20 27 440 447 I-clinical_variable
( 28 29 448 449 I-clinical_variable
HLA 29 32 449 452 I-clinical_variable
) 32 33 452 453 I-clinical_variable
type 34 38 454 458 O
; 38 39 458 459 O
( 40 41 460 461 O
historic 41 49 461 469 O
HLA 50 53 470 473 O
typing 54 60 474 480 O
is 61 63 481 483 O
permitted 64 73 484 493 O
) 73 74 493 494 O

Chemotherapy 0 12 495 507 B-treatment
, 12 13 507 508 O
radiation 14 23 509 518 B-treatment
therapy 24 31 519 526 I-treatment
, 31 32 526 527 O
or 33 35 528 530 O
immunotherapy 36 49 531 544 B-treatment
within 50 56 545 551 O
4 57 58 552 553 B-upper_bound
weeks 59 64 554 559 I-upper_bound
prior 65 70 560 565 I-upper_bound
to 71 73 566 568 O
first 74 79 569 574 O
dosing 80 86 575 581 O
of 87 89 582 584 O
study 90 95 585 590 B-treatment
drug 96 100 591 595 I-treatment
( 101 102 596 597 O
6 102 103 597 598 B-upper_bound
weeks 104 109 599 604 I-upper_bound
for 110 113 605 608 O
nitrosoureas 114 126 609 621 B-treatment
) 126 127 621 622 O

Concomitant 0 11 623 634 O
systemic 12 20 635 643 B-treatment
treatment 21 30 644 653 I-treatment
with 31 35 654 658 O
chronic 36 43 659 666 O
use 44 47 667 670 O
( 48 49 671 672 O
based 49 54 672 677 O
on 55 57 678 680 O
the 58 61 681 684 O
investigator 62 74 685 697 O
's 74 76 697 699 O
judgment 77 85 700 708 O
) 85 86 708 709 O
of 87 89 710 712 O
corticosteroids 90 105 713 728 B-treatment
, 105 106 728 729 O
anti 107 111 730 734 B-treatment
- 111 112 734 735 I-treatment
histamine 112 121 735 744 I-treatment
or 122 124 745 747 O
non 125 128 748 751 B-treatment
- 128 129 751 752 I-treatment
steroidal 129 138 752 761 I-treatment
anti 139 143 762 766 I-treatment
- 143 144 766 767 I-treatment
inflammatory 144 156 767 779 I-treatment
drugs 157 162 780 785 I-treatment
, 162 163 785 786 O
and 164 167 787 790 O
other 168 173 791 796 B-treatment
platelet 174 182 797 805 I-treatment
inhibitory 183 193 806 816 I-treatment
agents 194 200 817 823 I-treatment

Eligible 0 8 824 832 O
patients 9 17 833 841 O
will 18 22 842 846 O
be 23 25 847 849 O
women 26 31 850 855 O
with 32 36 856 860 O
epithelial 37 47 861 871 B-cancer
ovarian 48 55 872 879 I-cancer
, 55 56 879 880 O
fallopian 57 66 881 890 B-cancer
tube 67 71 891 895 I-cancer
, 71 72 895 896 O
or 73 75 897 899 O
primary 76 83 900 907 O
peritoneal 84 94 908 918 B-cancer
carcinoma 95 104 919 928 I-cancer
after 105 110 929 934 O
chemotherapy 111 123 935 947 B-treatment
with 124 128 948 952 O
no 129 131 953 955 O
evidence 132 140 956 964 O
of 141 143 965 967 O
disease 144 151 968 975 O
or 152 154 976 978 O
minimal 155 162 979 986 B-cancer
residual 163 171 987 995 I-cancer
disease 172 179 996 1003 I-cancer
for 180 183 1004 1007 O
primary 184 191 1008 1015 O
or 192 194 1016 1018 O
recurrent 195 204 1019 1028 O
disease 205 212 1029 1036 O
; 212 213 1036 1037 O
this 214 218 1038 1042 O
may 219 222 1043 1046 O
or 223 225 1047 1049 O
may 226 229 1050 1053 O
not 230 233 1054 1057 O
be 234 236 1058 1060 O
measurable 237 247 1061 1071 O
; 247 248 1071 1072 O
these 249 254 1073 1078 O
patients 255 263 1079 1087 O
would 264 269 1088 1093 O
normally 270 278 1094 1102 O
enter 279 284 1103 1108 O
a 285 286 1109 1110 O
period 287 293 1111 1117 O
of 294 296 1118 1120 O
observation 297 308 1121 1132 O
after 309 314 1133 1138 O
standard 315 323 1139 1147 O
management 324 334 1148 1158 O

Evidence 0 8 1159 1167 O
of 9 11 1168 1170 O
current 12 19 1171 1178 O
drug 20 24 1179 1183 O
or 25 27 1184 1186 O
alcohol 28 35 1187 1194 O
abuse 36 41 1195 1200 O
or 42 44 1201 1203 O
psychiatric 45 56 1204 1215 B-chronic_disease
impairment 57 67 1216 1226 I-chronic_disease
, 67 68 1226 1227 O
which 69 74 1228 1233 O
in 75 77 1234 1236 O
the 78 81 1237 1240 O
Investigator 82 94 1241 1253 O
's 94 96 1253 1255 O
opinion 97 104 1256 1263 O
will 105 109 1264 1268 O
prevent 110 117 1269 1276 O
completion 118 128 1277 1287 O
of 129 131 1288 1290 O
the 132 135 1291 1294 O
protocol 136 144 1295 1303 O
therapy 145 152 1304 1311 B-treatment
or 153 155 1312 1314 O
follow 156 162 1315 1321 O
- 162 163 1321 1322 O
up 163 165 1322 1324 O

Have 0 4 1325 1329 O
an 5 7 1330 1332 O
Eastern 8 15 1333 1340 B-clinical_variable
Cooperative 16 27 1341 1352 I-clinical_variable
Oncology 28 36 1353 1361 I-clinical_variable
Group 37 42 1362 1367 I-clinical_variable
( 43 44 1368 1369 I-clinical_variable
ECOG 44 48 1369 1373 I-clinical_variable
) 48 49 1373 1374 I-clinical_variable
performance 50 61 1375 1386 I-clinical_variable
status 62 68 1387 1393 I-clinical_variable
of 69 71 1394 1396 O
= 72 73 1397 1398 O
< 73 74 1398 1399 O
2 75 76 1400 1401 B-upper_bound

Have 0 4 1402 1406 O
been 5 9 1407 1411 O
informed 10 18 1412 1420 O
of 19 21 1421 1423 O
other 22 27 1424 1429 O
treatment 28 37 1430 1439 B-treatment
options 38 45 1440 1447 O

Hemoglobin 0 10 1448 1458 B-clinical_variable
( 11 12 1459 1460 I-clinical_variable
Hgb 12 15 1460 1463 I-clinical_variable
) 15 16 1463 1464 I-clinical_variable
> 17 18 1465 1466 O
= 18 19 1466 1467 O
8 20 21 1468 1469 B-lower_bound
g 22 23 1470 1471 I-lower_bound
/ 23 24 1471 1472 I-lower_bound
dL 24 26 1472 1474 I-lower_bound

History 0 7 1475 1482 O
of 8 10 1483 1485 O
severe 11 17 1486 1492 O
autoimmune 18 28 1493 1503 B-chronic_disease
disorders 29 38 1504 1513 I-chronic_disease
requiring 39 48 1514 1523 O
use 49 52 1524 1527 O
of 53 55 1528 1530 O
steroids 56 64 1531 1539 B-treatment
or 65 67 1540 1542 O
other 68 73 1543 1548 O
immunosuppressives 74 92 1549 1567 B-treatment

Known 0 5 1568 1573 O
hepatitis 6 15 1574 1583 B-chronic_disease
B 16 17 1584 1585 I-chronic_disease
, 17 18 1585 1586 O
hepatitis 19 28 1587 1596 B-chronic_disease
C 29 30 1597 1598 I-chronic_disease
, 30 31 1598 1599 O
or 32 34 1600 1602 O
human 35 40 1603 1608 B-treatment
immunodeficiency 41 57 1609 1625 I-treatment
virus 58 63 1626 1631 I-treatment
( 64 65 1632 1633 I-treatment
HIV 65 68 1633 1636 I-treatment
) 68 69 1636 1637 I-treatment

Life 0 4 1638 1642 B-clinical_variable
expectancy 5 15 1643 1653 I-clinical_variable
> 16 17 1654 1655 O
6 18 19 1656 1657 B-lower_bound
months 20 26 1658 1664 I-lower_bound

Mental 0 6 1665 1671 B-chronic_disease
impairment 7 17 1672 1682 I-chronic_disease
that 18 22 1683 1687 O
may 23 26 1688 1691 O
compromise 27 37 1692 1702 O
the 38 41 1703 1706 O
ability 42 49 1707 1714 O
to 50 52 1715 1717 O
give 53 57 1718 1722 O
informed 58 66 1723 1731 O
consent 67 74 1732 1739 O
and 75 78 1740 1743 O
comply 79 85 1744 1750 O
with 86 90 1751 1755 O
the 91 94 1756 1759 O
requirements 95 107 1760 1772 O
of 108 110 1773 1775 O
the 111 114 1776 1779 O
study 115 120 1780 1785 O

Metastatic 0 10 1786 1796 B-cancer
disease 11 18 1797 1804 I-cancer
to 19 21 1805 1807 O
the 22 25 1808 1811 O
central 26 33 1812 1819 O
nervous 34 41 1820 1827 O
system 42 48 1828 1834 O
for 49 52 1835 1838 O
which 53 58 1839 1844 O
other 59 64 1845 1850 O
therapeutic 65 76 1851 1862 O
options 77 84 1863 1870 O
, 84 85 1870 1871 O
including 86 95 1872 1881 O
radiotherapy 96 108 1882 1894 B-treatment
, 108 109 1894 1895 O
may 110 113 1896 1899 O
be 114 116 1900 1902 O
available 117 126 1903 1912 O

Other 0 5 1913 1918 O
serious 6 13 1919 1926 B-chronic_disease
illnesses 14 23 1927 1936 I-chronic_disease
( 24 25 1937 1938 O
e.g. 25 29 1938 1942 O
, 29 30 1942 1943 O
serious 31 38 1944 1951 B-chronic_disease
infections 39 49 1952 1962 I-chronic_disease
requiring 50 59 1963 1972 O
antibiotics 60 71 1973 1984 B-treatment
, 71 72 1984 1985 O
bleeding 73 81 1986 1994 B-chronic_disease
disorders 82 91 1995 2004 I-chronic_disease
) 91 92 2004 2005 O

Participation 0 13 2006 2019 O
in 14 16 2020 2022 O
any 17 20 2023 2026 B-treatment
other 21 26 2027 2032 I-treatment
clinical 27 35 2033 2041 I-treatment
trial 36 41 2042 2047 I-treatment
involving 42 51 2048 2057 I-treatment
another 52 59 2058 2065 I-treatment
investigational 60 75 2066 2081 I-treatment
agent 76 81 2082 2087 I-treatment
within 82 88 2088 2094 O
4 89 90 2095 2096 B-upper_bound
weeks 91 96 2097 2102 I-upper_bound
prior 97 102 2103 2108 I-upper_bound
to 103 105 2109 2111 O
first 106 111 2112 2117 O
dosing 112 118 2118 2124 O
of 119 121 2125 2127 O
study 122 127 2128 2133 O
drug 128 132 2134 2138 O

Patients 0 8 2139 2147 O
may 9 12 2148 2151 O
have 13 17 2152 2156 O
received 18 26 2157 2165 O
previous 27 35 2166 2174 B-treatment
NY 36 38 2175 2177 I-treatment
- 38 39 2177 2178 I-treatment
ESO-1 39 44 2178 2183 I-treatment
vaccine 45 52 2184 2191 I-treatment
therapy 53 60 2192 2199 I-treatment
; 60 61 2199 2200 O
patients 62 70 2201 2209 O
who 71 74 2210 2213 O
received 75 83 2214 2222 O
maintenance 84 95 2223 2234 O
paclitaxel 96 106 2235 2245 B-treatment
or 107 109 2246 2248 O
bevacizumab 110 121 2249 2260 B-treatment
are 122 125 2261 2264 O
eligible 126 134 2265 2273 O
for 135 138 2274 2277 O
enrollment 139 149 2278 2288 O
provided 150 158 2289 2297 O
they 159 163 2298 2302 O
have 164 168 2303 2307 O
discontinued 169 181 2308 2320 O
therapy 182 189 2321 2328 O
( 190 191 2329 2330 O
at 191 193 2330 2332 O
least 194 199 2333 2338 O
4 200 201 2339 2340 B-lower_bound
weeks 202 207 2341 2346 I-lower_bound
for 208 211 2347 2350 I-lower_bound
prior 212 217 2351 2356 I-lower_bound
taxane 218 224 2357 2363 B-treatment
or 225 227 2364 2366 O
prior 228 233 2367 2372 O
bevacizumab 234 245 2373 2384 O
) 245 246 2384 2385 O
prior 247 252 2386 2391 O
to 253 255 2392 2394 O
randomization 256 269 2395 2408 O
and 270 273 2409 2412 O
recovered 274 283 2413 2422 O
from 284 288 2423 2427 O
toxicities 289 299 2428 2438 O
to 300 302 2439 2441 O
less 303 307 2442 2446 O
than 308 312 2447 2451 O
grade 313 318 2452 2457 B-upper_bound
2 319 320 2458 2459 I-upper_bound

Patients 0 8 2460 2468 O
of 9 11 2469 2471 O
child 12 17 2472 2477 O
- 17 18 2477 2478 O
bearing 18 25 2478 2485 O
potential 26 35 2486 2495 O
must 36 40 2496 2500 O
agree 41 46 2501 2506 B-contraception_consent
to 47 49 2507 2509 I-contraception_consent
use 50 53 2510 2513 I-contraception_consent
acceptable 54 64 2514 2524 I-contraception_consent
contraceptive 65 78 2525 2538 I-contraception_consent
methods 79 86 2539 2546 I-contraception_consent
( 87 88 2547 2548 O
e.g. 88 92 2548 2552 O
, 92 93 2552 2553 O
double 94 100 2554 2560 B-contraception_consent
barrier 101 108 2561 2568 I-contraception_consent
) 108 109 2568 2569 O
during 110 116 2570 2576 O
treatment 117 126 2577 2586 B-treatment

Platelets 0 9 2587 2596 B-clinical_variable
( 10 11 2597 2598 I-clinical_variable
PLT 11 14 2598 2601 I-clinical_variable
) 14 15 2601 2602 I-clinical_variable
> 16 17 2603 2604 O
= 17 18 2604 2605 O
100,000 19 26 2606 2613 B-lower_bound
/ 26 27 2613 2614 I-lower_bound
uL 27 29 2614 2616 I-lower_bound

Pregnant 0 8 2617 2625 B-pregnancy

Serum 0 5 2626 2631 B-clinical_variable
aspartate 6 15 2632 2641 I-clinical_variable
aminotransferase 16 32 2642 2658 I-clinical_variable
( 33 34 2659 2660 I-clinical_variable
serum 34 39 2660 2665 I-clinical_variable
glutamic 40 48 2666 2674 I-clinical_variable
oxaloacetic 49 60 2675 2686 I-clinical_variable
transaminase 61 73 2687 2699 I-clinical_variable
[ 74 75 2700 2701 I-clinical_variable
SGOT]/AST 75 84 2701 2710 I-clinical_variable
) 84 85 2710 2711 I-clinical_variable
or 86 88 2712 2714 O
serum 89 94 2715 2720 B-clinical_variable
alanine 95 102 2721 2728 I-clinical_variable
aminotransferase 103 119 2729 2745 I-clinical_variable
( 120 121 2746 2747 I-clinical_variable
serum 121 126 2747 2752 I-clinical_variable
glutamate 127 136 2753 2762 I-clinical_variable
pyruvate 137 145 2763 2771 I-clinical_variable
transaminase 146 158 2772 2784 I-clinical_variable
[ 159 160 2785 2786 I-clinical_variable
SGPT]/ALT 160 169 2786 2795 I-clinical_variable
) 169 170 2795 2796 I-clinical_variable
= 171 172 2797 2798 O
< 172 173 2798 2799 O
3 174 175 2800 2801 B-upper_bound
x 176 177 2802 2803 I-upper_bound
ULN 178 181 2804 2807 I-upper_bound

Serum 0 5 2808 2813 B-clinical_variable
creatinine 6 16 2814 2824 I-clinical_variable
= 17 18 2825 2826 O
< 18 19 2826 2827 O
2 20 21 2828 2829 B-upper_bound
x 22 23 2830 2831 I-upper_bound
ULN 24 27 2832 2835 I-upper_bound

Subjects 0 8 2836 2844 O
being 9 14 2845 2850 O
treated 15 22 2851 2858 O
with 23 27 2859 2863 O
a 28 29 2864 2865 O
monoamine 30 39 2866 2875 B-treatment
oxidase 40 47 2876 2883 I-treatment
inhibitor 48 57 2884 2893 I-treatment
( 58 59 2894 2895 I-treatment
MAOI 59 63 2895 2899 I-treatment
) 63 64 2899 2900 I-treatment
, 64 65 2900 2901 O
or 66 68 2902 2904 O
drug 69 73 2905 2909 O
which 74 79 2910 2915 O
has 80 83 2916 2919 O
significant 84 95 2920 2931 O
MAOI 96 100 2932 2936 O
activity 101 109 2937 2945 O
( 110 111 2946 2947 O
e.g. 111 115 2947 2951 O
, 115 116 2951 2952 O
Meperidine 117 127 2953 2963 B-treatment
, 127 128 2963 2964 O
linezolid 129 138 2965 2974 B-treatment
, 138 139 2974 2975 O
methylene 140 149 2976 2985 B-treatment
blue 150 154 2986 2990 I-treatment
) 154 155 2990 2991 O
within 156 162 2992 2998 O
3 163 164 2999 3000 B-upper_bound
weeks 165 170 3001 3006 I-upper_bound
prior 171 176 3007 3012 I-upper_bound
to 177 179 3013 3015 O
screening 180 189 3016 3025 O

Subjects 0 8 3026 3034 O
who 9 12 3035 3038 O
are 13 16 3039 3042 O
currently 17 26 3043 3052 O
receiving 27 36 3053 3062 O
therapy 37 44 3063 3070 B-treatment
with 45 49 3071 3075 I-treatment
a 50 51 3076 3077 I-treatment
potent 52 58 3078 3084 I-treatment
cytochrome 59 69 3085 3095 I-treatment
P450 70 74 3096 3100 I-treatment
, 74 75 3100 3101 O
family 76 82 3102 3108 B-treatment
3 83 84 3109 3110 I-treatment
, 84 85 3110 3111 O
subfamily 86 95 3112 3121 B-treatment
A 96 97 3122 3123 I-treatment
, 97 98 3123 3124 O
polypeptide 99 110 3125 3136 B-treatment
4 111 112 3137 3138 I-treatment
( 113 114 3139 3140 I-treatment
CYP3A4 114 120 3140 3146 I-treatment
) 120 121 3146 3147 I-treatment
inducer 122 129 3148 3155 I-treatment
or 130 132 3156 3158 O
inhibitor 133 142 3159 3168 O
( 143 144 3169 3170 O
e.g. 144 148 3170 3174 O
clarithromycin 149 163 3175 3189 B-treatment
, 163 164 3189 3190 O
telithromycin 165 178 3191 3204 B-treatment
, 178 179 3204 3205 O
nefazodone 180 190 3206 3216 B-treatment
, 190 191 3216 3217 O
itraconazole 192 204 3218 3230 B-treatment
, 204 205 3230 3231 O
ketoconazole 206 218 3232 3244 B-treatment
, 218 219 3244 3245 O
atazanavir 220 230 3246 3256 B-treatment
) 230 231 3256 3257 O

The 0 3 3258 3261 O
ability 4 11 3262 3269 O
to 12 14 3270 3272 O
swallow 15 22 3273 3280 O
and 23 26 3281 3284 O
retain 27 33 3285 3291 O
oral 34 38 3292 3296 O
medication 39 49 3297 3307 B-treatment

Total 0 5 3308 3313 B-clinical_variable
bilirubin 6 15 3314 3323 I-clinical_variable
= 16 17 3324 3325 O
< 17 18 3325 3326 O
1.5 19 22 3327 3330 B-upper_bound
x 23 24 3331 3332 I-upper_bound
upper 25 30 3333 3338 I-upper_bound
limit 31 36 3339 3344 I-upper_bound
of 37 39 3345 3347 I-upper_bound
normal 40 46 3348 3354 I-upper_bound
( 47 48 3355 3356 I-upper_bound
ULN 48 51 3356 3359 I-upper_bound
) 51 52 3359 3360 I-upper_bound

Tumor 0 5 3361 3366 B-cancer
expression 6 16 3367 3377 O
of 17 19 3378 3380 O
NY 20 22 3381 3383 O
- 22 23 3383 3384 O
ESO-1 23 28 3384 3389 O
or 29 31 3390 3392 O
LAGE-1 32 38 3393 3399 O
by 39 41 3400 3402 O
immunohistochemistry 42 62 3403 3423 B-treatment
( 63 64 3424 3425 I-treatment
IHC 64 67 3425 3428 I-treatment
) 67 68 3428 3429 I-treatment
and/or 69 75 3430 3436 O
reverse 76 83 3437 3444 O
transcriptase 84 97 3445 3458 O
polymerase 98 108 3459 3469 O
chain 109 114 3470 3475 O
reaction 115 123 3476 3484 O
( 124 125 3485 3486 O
RTPCR 125 130 3486 3491 O
) 130 131 3491 3492 O

Use 0 3 3493 3496 O
of 4 6 3497 3499 O
UDP 7 10 3500 3503 B-treatment
glucuronosyltransferase 11 34 3504 3527 I-treatment
1 35 36 3528 3529 O
family 37 43 3530 3536 O
, 43 44 3536 3537 O
polypeptide 45 56 3538 3549 B-treatment
A9 57 59 3550 3552 I-treatment
( 60 61 3553 3554 I-treatment
UGT1A9 61 67 3554 3560 I-treatment
) 67 68 3560 3561 I-treatment
inhibitor 69 78 3562 3571 I-treatment
including 79 88 3572 3581 O
: 88 89 3581 3582 O
diclofenac 90 100 3583 3593 B-treatment
, 100 101 3593 3594 O
imipramine 102 112 3595 3605 B-treatment
, 112 113 3605 3606 O
and 114 117 3607 3610 O
ketoconazole 118 130 3611 3623 B-treatment

nursing 0 7 3624 3631 O
female 8 14 3632 3638 B-gender
patients 15 23 3639 3647 I-gender

